$11.14
4.21%
Nasdaq, Apr 21, 08:47 pm CET
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$11.63
-1.56 11.83% 1M
+1.40 13.69% 6M
-0.41 3.41% YTD
+7.16 159.89% 1Y
+5.35 85.19% 3Y
-1.37 10.54% 5Y
-2,018,799,988.37 100.00% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.08 0.69%
ISIN
US24661P5008
Symbol
DCTH
Sector

Key metrics

Market capitalization $388.82m
Enterprise Value $336.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.05
P/S ratio (TTM) P/S ratio 10.45
P/B ratio (TTM) P/B ratio 5.59
Revenue growth (TTM) Revenue growth 1,701.69%
Revenue (TTM) Revenue $37.21m
EBIT (operating result TTM) EBIT $-12.41m
Free Cash Flow (TTM) Free Cash Flow $-19.24m
Cash position $53.23m
EPS (TTM) EPS $-0.98
P/E forward negative
P/S forward 4.70
EV/Sales forward 4.07
Short interest 2.62%
Show more

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

Buy
100%

Financial data from Delcath Systems Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
37 37
1,698% 1,698%
100%
- Direct Costs 6.19 6.19
501% 501%
17%
31 31
2,883% 2,883%
83%
- Selling and Administrative Expenses 29 29
37% 37%
79%
- Research and Development Expense 14 14
21% 21%
37%
-12 -12
68% 68%
-32%
- Depreciation and Amortization 0.33 0.33
15% 15%
1%
EBIT (Operating Income) EBIT -12 -12
67% 67%
-33%
Net Profit -26 -26
45% 45%
-71%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Business Wire
12 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis from the randomized cohort of the Company's Phase 3 FOCUS study in Annals of Surgical Oncology. The study, titled “An Open-label, Randomized Study of Melphalan/Hepat...
Negative
Seeking Alpha
19 days ago
Delcath Systemsbeat Q4 sales estimates. This was driven by increased adoption of HEPZATO KIT. However, the stock fell due to the Biotech/Medtech bear market. Delcath reported its first profitable quarter with adjusted EBITDA of $4.6 million. It has a strong cash position which will be used for its two Phase 2 trials. European expansion faces reimbursement challenges, but growing usage & the CHO...
Neutral
Business Wire
28 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in the CG Horizons in Oncology Virtual Conference on April 7, 2025 at 10:00 a.m. ET. Investors interested in participating should contact their Canaccord representativ...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Gerard Michel
Employees 96
Founded 1988
Website www.delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today